Cost advantages of oral drug therapy for managing cytomegalovirus disease.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Volumn 60, Issue 23 Suppl 8, 2003, Pages

  Somerville, K Troy ^a  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; GANCICLOVIR;

ANTIBIOTIC PROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; CYTOMEGALIC INCLUSION BODY DISEASE; ECONOMICS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; VIROLOGY;

ADMINISTRATION, ORAL; ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; IMMUNOSUPPRESSION; LIVER TRANSPLANTATION; OPPORTUNISTIC INFECTIONS; RANDOMIZED CONTROLLED TRIALS;

EID: 1542540307     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (8)